中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
10期
6-13
,共8页
新辅助化疗%非小细胞肺癌%预后%Meta分析
新輔助化療%非小細胞肺癌%預後%Meta分析
신보조화료%비소세포폐암%예후%Meta분석
Neoadjuvant chemotherapy%NSCLC%Prognosis%Meta-analysis
目的 应用Meta分析的方法探讨新辅助化疗对非小细胞肺癌预后的影响.方法 系统检索2个中文数据库(万方、维普)及2个英文数据库(PubMed、Cochrane Library)截止2013年6月发表的有关非小细胞肺癌新辅助化疗的随机临床对照试验,分别对入选文献进行评价,最后提取资料进行Meta分析.结果 纳入符合标准文献共17篇,新辅助化疗组1879例,直接手术组1898例,分析结果显示,与直接手术组相比,新辅助化疗组死亡风险优势比OR=0.75,95％可信区间为(0.66 ～0.87),差异有统计学意义(P＜0.01).对Ⅲ期患者进行亚组分析,OR=0.59,95％可信区间为(0.48 ～0.72),差异有统计学意义(P＜0.01).对Jadad评分=3的研究进行分析,OR=0.79,95％可信区间为(0.67 ～0.93),差异有统计学意义(P =0.006).结论 与直接手术相比,新辅助化疗能提高非小细胞肺癌患者的术后长期生存率,但不能断定新辅助化疗能提高非小细胞肺癌患者术后长期生存率,需要进一步研究.
目的 應用Meta分析的方法探討新輔助化療對非小細胞肺癌預後的影響.方法 繫統檢索2箇中文數據庫(萬方、維普)及2箇英文數據庫(PubMed、Cochrane Library)截止2013年6月髮錶的有關非小細胞肺癌新輔助化療的隨機臨床對照試驗,分彆對入選文獻進行評價,最後提取資料進行Meta分析.結果 納入符閤標準文獻共17篇,新輔助化療組1879例,直接手術組1898例,分析結果顯示,與直接手術組相比,新輔助化療組死亡風險優勢比OR=0.75,95％可信區間為(0.66 ～0.87),差異有統計學意義(P＜0.01).對Ⅲ期患者進行亞組分析,OR=0.59,95％可信區間為(0.48 ～0.72),差異有統計學意義(P＜0.01).對Jadad評分=3的研究進行分析,OR=0.79,95％可信區間為(0.67 ～0.93),差異有統計學意義(P =0.006).結論 與直接手術相比,新輔助化療能提高非小細胞肺癌患者的術後長期生存率,但不能斷定新輔助化療能提高非小細胞肺癌患者術後長期生存率,需要進一步研究.
목적 응용Meta분석적방법탐토신보조화료대비소세포폐암예후적영향.방법 계통검색2개중문수거고(만방、유보)급2개영문수거고(PubMed、Cochrane Library)절지2013년6월발표적유관비소세포폐암신보조화료적수궤림상대조시험,분별대입선문헌진행평개,최후제취자료진행Meta분석.결과 납입부합표준문헌공17편,신보조화료조1879례,직접수술조1898례,분석결과현시,여직접수술조상비,신보조화료조사망풍험우세비OR=0.75,95％가신구간위(0.66 ～0.87),차이유통계학의의(P＜0.01).대Ⅲ기환자진행아조분석,OR=0.59,95％가신구간위(0.48 ～0.72),차이유통계학의의(P＜0.01).대Jadad평분=3적연구진행분석,OR=0.79,95％가신구간위(0.67 ～0.93),차이유통계학의의(P =0.006).결론 여직접수술상비,신보조화료능제고비소세포폐암환자적술후장기생존솔,단불능단정신보조화료능제고비소세포폐암환자술후장기생존솔,수요진일보연구.
Objective To evaluate the effect of neoadjuvant chemotherapy on the prognosis of patients with NSCLC by Meta-analysis.Methods A systematic search of 2 Chinese electronic databases (Wanfang,VIP),and 3 English database (Pubmed,Cochrane Library) up to June 2013 was performed for the Randomized clinical trials (RCTs),Meta-analysis was made for the RCTs by Revman 4.2.Results There were 17 RCTs enrolled in this present Meta-analysis(1879 in neoadjuvant chemotherapy plus surgery group; 1898 in surgery group).There was significant difference between the neoadjuvant chemotherapy plus surgery group(study group) and surgery group (control group),OR (odds radio) =0.75(95％ CI 0.66-0.87),P ＜0.01.Also,There was significant difference between the study group and the surgery group in stage Ⅲ NSCLC,OR(odds radio) =0.59 (95％ CI 0.48-0.72),P ＜0.01.After further analysis,there was also significant difference between the study group and control group (Jadad =3),OR =0.79 (95 ％ CI 0.67-0.93),P =0.006.Conclusions Meta-analysis shows a benefit of neoadjuvant chemotherapy to the patients with resectable NSCLC in postoperative long-term survival rate.However,It is not certain that neoadjuvant chemotherapy can improve the postoperative longterm survival rate in NSCLC.It needs further trials.
